Literature DB >> 9354437

Inhibition of human cytochrome P450-catalyzed oxidations of xenobiotics and procarcinogens by synthetic organoselenium compounds.

T Shimada1, K El-Bayoumy, P Upadhyaya, T R Sutter, F P Guengerich, H Yamazaki.   

Abstract

The effects of synthetic chemopreventive organoselenium compounds 1,2-, 1,3-, and 1,4-phenylenebis(methylene)selenocyanate (o-, m-, and p-XSC, respectively), benzyl selenocyanate (BSC), and dibenzyl diselenide (DDS) and inorganic sodium selenite on the oxidation of xenobiotics and procarcinogens by human cytochrome P450 (P450 or CYP) enzymes were determined in vitro. Spectral studies showed that BSC and three XSC compounds (but not sodium selenite or DDS) induced type II difference spectrum when added to the suspension of liver microsomes isolated from beta-naphthoflavone-treated rats, with m-XSC being the most potent in inducing spectral interactions with P450 enzymes; m-XSC also produced a type II spectral change with human liver microsomes. o-, m-, and p-XSC inhibited 7-ethoxyresorufin O-deethylation catalyzed by human liver microsomes when added at concentrations below 1 microM levels, but BSC and DDS were less effective. All of these compounds inhibited the oxidation of model substrates for human P450s to varying extents. We studied the effects of these compounds on the activation of procarcinogens by recombinant human CYP1A1, 1A2, and 1B1 enzymes using Salmonella typhimurium NM2009 tester strain for the detection of DNA damage. The three XSCs were found to be very potent inhibitors of metabolic activation of 3-amino-1,4-dimethyl-5H-pyrido[4,3-b]indole, 2-amino-3,5-dimethylimidazo[4,5-f]quinoline, and 2-aminoanthracene, catalyzed by CYP1A1, 1A2, and 1B1, respectively. The potency of inhibition of m-XSC on CYP1B1-dependent activation of 2-aminoanthracene was compatible to those of alpha-naphthoflavone. These inhibitory actions may, in part, account for the mechanisms responsible for cancer prevention by organoselenium compounds in laboratory animals.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9354437

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

Review 1.  Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2021-01-18       Impact factor: 5.153

2.  Murine hepatoma (Hepa1c1c7) cells: a responsive in vitro system for chemoprotective enzyme induction by organoselenium compounds.

Authors:  Wael M El-Sayed; Tarek Aboul-Fadl; Jeanette C Roberts; John G Lamb; Michael R Franklin
Journal:  Toxicol In Vitro       Date:  2006-10-07       Impact factor: 3.500

3.  Specificity determinants of CYP1B1 estradiol hydroxylation.

Authors:  Clinton R Nishida; Steven Everett; Paul R Ortiz de Montellano
Journal:  Mol Pharmacol       Date:  2013-07-02       Impact factor: 4.436

4.  Reverse type I binding spectra of human cytochrome P450 1B1 induced by flavonoid, stilbene, pyrene, naphthalene, phenanthrene, and biphenyl derivatives that inhibit catalytic activity: a structure-function relationship study.

Authors:  Tsutomu Shimada; Katsuhiro Tanaka; Shigeo Takenaka; Maryam K Foroozesh; Norie Murayama; Hiroshi Yamazaki; F Peter Guengerich; Masayuki Komori
Journal:  Chem Res Toxicol       Date:  2009-07       Impact factor: 3.739

5.  Spectral modification and catalytic inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2A6, and 2A13 by four chemopreventive organoselenium compounds.

Authors:  Tsutomu Shimada; Norie Murayama; Katsuhiro Tanaka; Shigeo Takenaka; F Peter Guengerich; Hiroshi Yamazaki; Masayuki Komori
Journal:  Chem Res Toxicol       Date:  2011-07-20       Impact factor: 3.739

Review 6.  Potential role of CYP1B1 in the development and treatment of metabolic diseases.

Authors:  Fei Li; Weifeng Zhu; Frank J Gonzalez
Journal:  Pharmacol Ther       Date:  2017-03-16       Impact factor: 12.310

7.  Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors.

Authors:  David J Granville; Babak Tashakkor; Cindy Takeuchi; Asa B Gustafsson; Chengqun Huang; M Richard Sayen; Paul Wentworth; Mark Yeager; Roberta A Gottlieb
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-20       Impact factor: 11.205

Review 8.  Manganese superoxide dismutase in cancer prevention.

Authors:  Delira Robbins; Yunfeng Zhao
Journal:  Antioxid Redox Signal       Date:  2013-07-18       Impact factor: 8.401

Review 9.  The selenium and vitamin E cancer prevention trial.

Authors:  Eric A Klein; Scott M Lippman; Ian M Thompson; Phyllis J Goodman; Demetrius Albanes; Philip R Taylor; Charles Coltman
Journal:  World J Urol       Date:  2003-03-08       Impact factor: 4.226

Review 10.  Development and progress for three decades in umu test systems.

Authors:  Yoshimitsu Oda
Journal:  Genes Environ       Date:  2016-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.